The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: A morphologic and molecular genetic analysis

American Journal of Surgical Pathology

Volumn 31, Issue 7, 2007, Pages 1007-1012

  Dehari, Reiko ^a,b   Kurman, Robert J ^a,b   Logani, Sanjay ^a,b   Shih, Ie Ming ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Borderline tumor; Ovarian cancer; Serous carcinoma

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL PROLIFERATION; CLONAL VARIATION; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MEDICAL RECORD REVIEW; MICRODISSECTION; MOLECULAR GENETICS; MORPHOLOGY; MUTATIONAL ANALYSIS; OVARY CARCINOMA; WILD TYPE;

ADULT; AGED; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; MICRODISSECTION; MIDDLE AGED; OVARIAN NEOPLASMS; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34347347175     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31802cbbe9     Document Type: Article

References (17)

1. Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer. 1994;73:1859-1864.
2. Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005;65:10602-10612.
3. Dansonka-Mieszkowska A, Ludwig AH, Kraszewska E, et al. Geographical variations in TP53 mutational spectrum in ovarian carcinomas. Ann Hum Genet. 2006;70:594-604.
4. Gadducci A, Di Cristofano C, Zavaglia M et al. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res. 2006;26:687-693.
5. Gilks CB, Vanderhyden BC, Zhu S, et al. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol. 2005;96:684-694.
6. Ho C-L, Kurman RJ, Dehari R, et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004;64:6915-6918.
7. Hsu CY, Kurman RJ, Vang R, et al. Nuclear size distinguishes low-from high-grade ovarian serous carcinoma and predicts outcome. Hum Pathol. 2005;36:1049-1054.
8. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene. 2005;24:1053-1065.
9. Milner BJ, Allan LA, Eccles DM, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res. 1993;53:2128-2132.
10. Nakayama K, Nakayama N, Kurman RJ, et al. Sequence mutations and amplificatin of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther. 2006;5:779-785.
11. Parker RL, Clement PB, Chercover DJ, et al. Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases. Int J Gynecol Pathol. 2004;23:265-272.
12. Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat. 2003;21:285-291.
13. Shih I-M, Kurman RJ. Ovarian tumorigenesis - a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511-1518.
14. Shih I-M, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res. 2005;11:7273-7279.
15. Singer G, Kurman RJ, Chang H-W, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160:1223-1228.
16. Singer G, Oldt R III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484-486.
17. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29:218-224.